• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The evolution of diagnosis from symptom onset to death in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) compared to Parkinson's disease (PD).对比帕金森病(PD),探讨进行性核上性麻痹(PSP)和皮质基底节变性(CBD)从症状出现到死亡的诊断演变过程。
J Neurol. 2023 Jul;270(7):3464-3474. doi: 10.1007/s00415-023-11629-x. Epub 2023 Mar 27.
2
Dopamine transporter SPECT imaging in Parkinson's disease and atypical Parkinsonism: a study of 137 patients.帕金森病和非典型帕金森综合征的多巴胺转运体单光子发射计算机断层扫描成像:137例患者的研究
Neurol Sci. 2023 May;44(5):1613-1623. doi: 10.1007/s10072-023-06628-9. Epub 2023 Jan 20.
3
PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage.在疾病早期,进行性核上性麻痹可通过临床和影像学差异与皮质基底节变性、多系统萎缩-P型及帕金森病相鉴别。
Intern Med. 2011;50(22):2775-81. doi: 10.2169/internalmedicine.50.5954. Epub 2011 Nov 15.
4
Presence of Skin α-Synuclein Deposits Discriminates Parkinson's Disease from Progressive Supranuclear Palsy and Corticobasal Syndrome.皮肤 α-突触核蛋白沉积的存在可将帕金森病与进行性核上性麻痹和皮质基底节综合征区分开来。
J Parkinsons Dis. 2022;12(2):585-591. doi: 10.3233/JPD-212904.
5
Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid.帕金森综合征患者脑脊液中的溶酶体网络蛋白特征明显不同。
J Parkinsons Dis. 2016 Apr 2;6(2):307-15. doi: 10.3233/JPD-150759.
6
Comparison of dystonia between Parkinson's disease and atypical parkinsonism: The clinical usefulness of dystonia distribution and characteristics in the differential diagnosis of parkinsonism.帕金森病与非典型帕金森综合征中肌张力障碍的比较:肌张力障碍分布及特征在帕金森综合征鉴别诊断中的临床应用价值
Neurol Neurochir Pol. 2018 Jan-Feb;52(1):48-53. doi: 10.1016/j.pjnns.2017.11.004. Epub 2017 Nov 14.
7
Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms.寡聚 α-突触核蛋白和 tau 聚集物在 NDEVs 中区分帕金森病与非典型帕金森病。
Neurobiol Dis. 2023 Jan;176:105947. doi: 10.1016/j.nbd.2022.105947. Epub 2022 Dec 5.
8
Parkinson's disease and parkinsonism: Clinicopathological discrepancies on diagnosis in three patients.帕金森病和帕金森综合征:3例患者诊断中的临床病理差异
Neuropathology. 2021 Dec;41(6):450-456. doi: 10.1111/neup.12777. Epub 2021 Nov 14.
9
Progression of falls in postmortem-confirmed parkinsonian disorders.尸检确诊的帕金森氏症中跌倒的进展情况。
Mov Disord. 1999 Nov;14(6):947-50. doi: 10.1002/1531-8257(199911)14:6<947::aid-mds1006>3.0.co;2-o.
10
Discriminating among degenerative parkinsonisms using advanced (123)I-ioflupane SPECT analyses.使用先进的(123)I-碘氟潘单光子发射计算机断层显像(SPECT)分析鉴别退行性帕金森综合征。
Neuroimage Clin. 2016 Jul 5;12:234-40. doi: 10.1016/j.nicl.2016.07.004. eCollection 2016.

引用本文的文献

1
Misdiagnosis of Frontotemporal Dementia in a Patient With Progressive Supranuclear Palsy: A Case Report and Volumetric Neuroimaging Application.一例进行性核上性麻痹患者的额颞叶痴呆误诊:病例报告及容积神经影像学应用
Cureus. 2025 Mar 29;17(3):e81421. doi: 10.7759/cureus.81421. eCollection 2025 Mar.
2
The potential of exosomal biomarkers: Revolutionizing Parkinson's disease: How do they influence pathogenesis, diagnosis, and therapeutic strategies?外泌体生物标志物的潜力:革新帕金森病:它们如何影响发病机制、诊断和治疗策略?
AIMS Neurosci. 2024 Sep 23;11(3):374-397. doi: 10.3934/Neuroscience.2024023. eCollection 2024.
3
Accuracy of routinely collected hospital administrative discharge data and death certificate ICD-10 diagnostic coding in progressive supranuclear palsy and corticobasal syndrome: a systematic review and validation study.在进行性核上性麻痹和皮质基底节综合征中,常规收集的医院行政出院数据和死亡证明 ICD-10 诊断编码的准确性:系统评价和验证研究。
J Neurol. 2024 Jun;271(6):2929-2937. doi: 10.1007/s00415-024-12280-w. Epub 2024 Apr 12.
4
Total Patient Delay: A Comparison of Patient and Clinician/Health System Delays in the Diagnosis of Progressive Supranuclear Palsy and Corticobasal Syndrome.总患者延迟:进行性核上性麻痹和皮质基底节综合征诊断中患者和临床医生/医疗系统延迟的比较。
Mov Disord Clin Pract. 2024 May;11(5):478-487. doi: 10.1002/mdc3.13990. Epub 2024 Feb 18.
5
The role of exosomes in the diagnosis of Parkinson's disease.外泌体在帕金森病诊断中的作用。
Heliyon. 2023 Oct 16;9(10):e20595. doi: 10.1016/j.heliyon.2023.e20595. eCollection 2023 Oct.

本文引用的文献

1
Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants.进行性核上性麻痹的临床进展:试验偏倚和表型变异的影响
Brain Commun. 2021 Sep 2;3(3):fcab206. doi: 10.1093/braincomms/fcab206. eCollection 2021.
2
Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: The step-back PSP study.进行性核上性麻痹的预诊断运动和非运动症状:后退 PSP 研究。
Parkinsonism Relat Disord. 2020 May;74:67-73. doi: 10.1016/j.parkreldis.2020.03.003. Epub 2020 Mar 13.
3
Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome.进行性核上性麻痹和皮质基底节综合征的谱系诊断。
JAMA Neurol. 2020 Mar 1;77(3):377-387. doi: 10.1001/jamaneurol.2019.4347.
4
Determinants of diagnostic latency in Chinese people with Parkinson's disease.中国帕金森病患者诊断延迟的决定因素。
BMC Neurol. 2019 Jun 11;19(1):120. doi: 10.1186/s12883-019-1323-5.
5
Is the Latency from Progressive Supranuclear Palsy Onset to Diagnosis Improving?进行性核上性麻痹从发病到诊断的时间间隔是否在缩短?
Mov Disord Clin Pract. 2018 Nov 8;5(6):603-606. doi: 10.1002/mdc3.12678. eCollection 2018 Nov-Dec.
6
Revision of assessment toolkits for improving the diagnosis of Lewy body dementia: The DIAMOND Lewy study.用于改善路易体痴呆诊断的评估工具包修订:钻石路易研究
Int J Geriatr Psychiatry. 2018 Oct;33(10):1293-1304. doi: 10.1002/gps.4948. Epub 2018 Aug 9.
7
Experience of care for Parkinson's disease in European countries: a survey by the European Parkinson's Disease Association.欧洲国家帕金森病护理经验:欧洲帕金森病协会调查。
Eur J Neurol. 2018 Dec;25(12):1410-e120. doi: 10.1111/ene.13738. Epub 2018 Aug 16.
8
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.进行性核上性麻痹的临床诊断:运动障碍协会标准。
Mov Disord. 2017 Jun;32(6):853-864. doi: 10.1002/mds.26987. Epub 2017 May 3.
9
Medium-term prognosis of an incident cohort of parkinsonian patients compared to controls.帕金森病患者发病队列与对照组的中期预后比较。
Parkinsonism Relat Disord. 2016 Nov;32:36-41. doi: 10.1016/j.parkreldis.2016.08.010. Epub 2016 Aug 12.
10
Risk of fracture amongst patients with Parkinson's disease and other forms of parkinsonism.帕金森病及其他帕金森症形式患者的骨折风险。
Parkinsonism Relat Disord. 2016 Aug;29:60-5. doi: 10.1016/j.parkreldis.2016.05.026. Epub 2016 May 26.

对比帕金森病(PD),探讨进行性核上性麻痹(PSP)和皮质基底节变性(CBD)从症状出现到死亡的诊断演变过程。

The evolution of diagnosis from symptom onset to death in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) compared to Parkinson's disease (PD).

机构信息

Institute of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK.

出版信息

J Neurol. 2023 Jul;270(7):3464-3474. doi: 10.1007/s00415-023-11629-x. Epub 2023 Mar 27.

DOI:10.1007/s00415-023-11629-x
PMID:36971841
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10266988/
Abstract

BACKGROUND

Misdiagnosis and delayed diagnosis in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are common. Few studies have systematically evaluated the diagnostic process from symptom onset to death in representative cohorts.

METHODS

All PSP/CBD cases (n = 28/2) and age-sex matched Parkinson's disease (PD) cases (n = 30) were identified from a UK prospective incident Parkinsonism cohort. Medical and research records were reviewed to compare median times from first index symptom to key diagnostic milestones and the nature/timing of secondary care referral and review.

RESULTS

Index symptoms were similar apart from more tremor in PD (p < 0.001) and more impaired balance (p = 0.008) and falls (p = 0.004) in PSP/CBD. PD was diagnosed a median 0.96 years after index symptom. In PSP/CBD the median times from index symptom to identifying parkinsonism and then including PSP/CBD in the differential diagnosis and the final diagnosis were 1.88, 3.41 and 4.03 years, respectively (all p < 0.001). Survival from symptom onset in PSP/CBD and PD was not significantly different (5.98 vs 6.85 years, p = 0.72). More diagnoses (p < 0.001) were considered in PSP/CBD. Prior to diagnosis, PSP/CBD patients had more recurrent emergency attendances (33.3% vs 10.0%, p = 0.01) and were referred to more specialities than PD (median 5 vs 2). Time to any outpatient referral (0.70 vs 0.03 years, p = 0.025) and to specialist movement disorder review (1.96 vs 0.57 years, p = 0.002) was longer in PSP/CBD.

CONCLUSIONS

The duration and complexity of the diagnostic journey were greater in PSP/CBD than age-sex matched PD but can be improved. In this older cohort, there was little difference in survival from symptom onset in PSP/CBD and age-sex matched PD.

摘要

背景

在进行性核上性麻痹(PSP)和皮质基底节变性(CBD)的诊断时,误诊和延迟诊断较为常见。很少有研究系统地评估过代表性队列中从症状出现到死亡的诊断过程。

方法

在英国前瞻性帕金森病队列中,我们确定了所有 PSP/CBD 病例(n=28/2)和年龄性别匹配的帕金森病(PD)病例(n=30)。我们回顾了医疗和研究记录,以比较从首发症状到关键诊断里程碑的中位数时间,以及二级保健转诊和复查的性质/时间。

结果

除 PD 中震颤更多(p<0.001)、PSP/CBD 中平衡障碍(p=0.008)和跌倒(p=0.004)更多外,首发症状相似。PD 的诊断中位时间为首发症状后 0.96 年。在 PSP/CBD 中,从首发症状到识别帕金森病,然后将 PSP/CBD 纳入鉴别诊断和最终诊断的中位数时间分别为 1.88、3.41 和 4.03 年(均 p<0.001)。PSP/CBD 和 PD 从症状出现到死亡的生存时间无显著差异(5.98 与 6.85 年,p=0.72)。PSP/CBD 考虑的诊断更多(p<0.001)。在诊断之前,PSP/CBD 患者的急诊就诊次数更多(33.3%与 10.0%,p=0.01),就诊科室多于 PD(中位数 5 与 2)。首次门诊转诊(0.70 与 0.03 年,p=0.025)和专科运动障碍复查(1.96 与 0.57 年,p=0.002)的时间在 PSP/CBD 中更长。

结论

与年龄性别匹配的 PD 相比,PSP/CBD 的诊断过程持续时间更长,复杂性更高,但可以改善。在这个年龄较大的队列中,PSP/CBD 和年龄性别匹配的 PD 从症状出现到死亡的生存时间几乎没有差异。